International Association of
Therapeutic Drug Monitoring and Clinical Toxicology
Fostering education, research and practice in TDM and CT

Pharmacogenetics Committee

Jesse Swen


Jesse Swen


Contact Us
Scientific Committees
Pharmacogenetics Committee

Nicolas Picard


Nicholas Picard

Background & Purpose of the Committee

  • To promote the knowledge about clinically relevant DNA testing to optimize drug therapy
  • To enhance the translation of research into clinical practice
  • To encourage discussions on the clinical relevance of specific pharmacogenetics tests, to encourage research into clinically important areas with respect to drug treatment
  • To encourage interaction between pharmacologist and toxicologist to promote "toxicogenetics"

Activities Planned/Committee Initiatives Currently in Progress

  • Make proposal for IATDMCT PGx session in the next Congress.
  • Propose/validate a (minimal) NGS panel to be used for pharmacogenetic applications in the field of TDM and CT (to be published in IATDMCT Compass).
  • Explore the need for updated PGx guidelines in immunosuppressive therapy.
  • Increase membership.

Past Years' Activities Held/Committee Initiatives

  • Informed members of IATDMCT on current discussions regarding PGx testing, on new potentially interesting pharmacogenetic markers, and the emergence of new technologies
  • Organization of 2 PGx sessions in Foz do Iguaçu 2019
    Morning session PGx on Tamoxifen (23/09/2019), Dr J. Swen and Dr Y. Tanigawara
    Symposium on PGx in oncology (25/09/2019) DPYD and 5-FU, Dr T. van Gelder; UGT1A1 and beyond, Dr J.C. Boyer; ABCG2 and TKIs Dr T. Terada

Publications, Scientific Contributions

  • Haufroid V and Picard N (2019) Pharmacogenetics biomarkers predictive of drug pharmacodynamics as an additional tool to therapeutic drug monitoring (invited editor: Shipkova M). Ther Drug Monit, 41: 121-130.
  • Haufroid V, Hesselink D, Elens L, MacPhee I, Masuda S, Picard N, van Gelder T, Van Schaik R (2019) Contribution to the “pharmacogenetic chapter” for the second consensus report on Tacrolimus TDM (invited editors: Brunet M and Bergan S). Ther Drug Monit, 41: 261-307.
  • Picard N and Haufroid V on behalf of the Pharmacogenetics Committee. Physician and pharmacist awareness and education about pharmacogenetics: The next challenge for clinical implementation? IATDMCT Compass December 2018: 9-10.
  • Haufroid V and Picard N on behalf of the Pharmacogenetics Committee. Genotyping versus Phenotyping: The case of fluoropyrimidines. IATDMCT Compass June 2019: 9-10.